vs

Side-by-side financial comparison of Abbott Laboratories (ABT) and MetLife (MET). Click either name above to swap in a different company.

MetLife is the larger business by last-quarter revenue ($19.1B vs $11.5B, roughly 1.7× Abbott Laboratories). Abbott Laboratories runs the higher net margin — 15.5% vs 6.0%, a 9.5% gap on every dollar of revenue. On growth, Abbott Laboratories posted the faster year-over-year revenue change (4.4% vs 2.7%). Over the past eight quarters, MetLife's revenue compounded faster (484.7% CAGR vs 7.2%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

MetLife, Inc. is the holding corporation for the Metropolitan Life Insurance Company (MLIC), better known as MetLife, and its affiliates. MetLife is among the largest global providers of insurance, annuities, and employee benefit programs, with around 90 million customers in over 60 countries. The firm was founded on March 24, 1868. MetLife ranked No. 43 in the 2018 Fortune 500 list of the largest United States corporations by total revenue.

ABT vs MET — Head-to-Head

Bigger by revenue
MET
MET
1.7× larger
MET
$19.1B
$11.5B
ABT
Growing faster (revenue YoY)
ABT
ABT
+1.7% gap
ABT
4.4%
2.7%
MET
Higher net margin
ABT
ABT
9.5% more per $
ABT
15.5%
6.0%
MET
Faster 2-yr revenue CAGR
MET
MET
Annualised
MET
484.7%
7.2%
ABT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABT
ABT
MET
MET
Revenue
$11.5B
$19.1B
Net Profit
$1.8B
$1.1B
Gross Margin
57.0%
Operating Margin
19.6%
Net Margin
15.5%
6.0%
Revenue YoY
4.4%
2.7%
Net Profit YoY
-80.8%
30.0%
EPS (diluted)
$1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABT
ABT
MET
MET
Q1 26
$19.1B
Q4 25
$11.5B
$600.0M
Q3 25
$11.4B
$621.0M
Q2 25
$11.1B
$604.0M
Q1 25
$10.4B
$611.0M
Q4 24
$11.0B
$556.0M
Q3 24
$10.6B
$554.0M
Q2 24
$10.4B
$558.0M
Net Profit
ABT
ABT
MET
MET
Q1 26
$1.1B
Q4 25
$1.8B
$809.0M
Q3 25
$1.6B
$896.0M
Q2 25
$1.8B
$729.0M
Q1 25
$1.3B
$945.0M
Q4 24
$9.2B
$1.3B
Q3 24
$1.6B
$1.3B
Q2 24
$1.3B
$946.0M
Gross Margin
ABT
ABT
MET
MET
Q1 26
Q4 25
57.0%
Q3 25
55.4%
Q2 25
56.4%
Q1 25
56.9%
Q4 24
55.0%
Q3 24
55.8%
Q2 24
55.6%
Operating Margin
ABT
ABT
MET
MET
Q1 26
Q4 25
19.6%
Q3 25
18.1%
Q2 25
18.4%
Q1 25
16.3%
Q4 24
17.4%
Q3 24
17.5%
Q2 24
16.1%
Net Margin
ABT
ABT
MET
MET
Q1 26
6.0%
Q4 25
15.5%
134.8%
Q3 25
14.5%
144.3%
Q2 25
16.0%
120.7%
Q1 25
12.8%
154.7%
Q4 24
84.1%
228.6%
Q3 24
15.5%
242.2%
Q2 24
12.5%
169.5%
EPS (diluted)
ABT
ABT
MET
MET
Q1 26
Q4 25
$1.01
$1.18
Q3 25
$0.94
$1.22
Q2 25
$1.01
$1.03
Q1 25
$0.76
$1.28
Q4 24
$5.26
$1.75
Q3 24
$0.94
$1.81
Q2 24
$0.74
$1.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABT
ABT
MET
MET
Cash + ST InvestmentsLiquidity on hand
$8.9B
Total DebtLower is stronger
$12.9B
$14.8B
Stockholders' EquityBook value
$52.1B
$27.6B
Total Assets
$86.7B
$743.2B
Debt / EquityLower = less leverage
0.25×
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABT
ABT
MET
MET
Q1 26
Q4 25
$8.9B
$25.6B
Q3 25
$7.7B
$26.2B
Q2 25
$7.3B
$27.5B
Q1 25
$6.8B
$26.9B
Q4 24
$8.0B
$25.2B
Q3 24
$7.8B
$26.4B
Q2 24
$7.2B
$24.6B
Total Debt
ABT
ABT
MET
MET
Q1 26
$14.8B
Q4 25
$12.9B
Q3 25
Q2 25
Q1 25
Q4 24
$14.1B
Q3 24
Q2 24
Stockholders' Equity
ABT
ABT
MET
MET
Q1 26
$27.6B
Q4 25
$52.1B
$28.4B
Q3 25
$51.0B
$28.9B
Q2 25
$50.6B
$27.7B
Q1 25
$48.8B
$27.5B
Q4 24
$47.7B
$27.4B
Q3 24
$39.8B
$30.9B
Q2 24
$39.3B
$27.3B
Total Assets
ABT
ABT
MET
MET
Q1 26
$743.2B
Q4 25
$86.7B
$745.2B
Q3 25
$84.2B
$719.7B
Q2 25
$84.0B
$702.5B
Q1 25
$81.4B
$688.3B
Q4 24
$81.4B
$677.5B
Q3 24
$74.4B
$705.0B
Q2 24
$73.0B
$675.7B
Debt / Equity
ABT
ABT
MET
MET
Q1 26
0.54×
Q4 25
0.25×
Q3 25
Q2 25
Q1 25
Q4 24
0.30×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABT
ABT
MET
MET
Operating Cash FlowLast quarter
$3.3B
Free Cash FlowOCF − Capex
$2.6B
FCF MarginFCF / Revenue
22.9%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
1.87×
TTM Free Cash FlowTrailing 4 quarters
$7.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABT
ABT
MET
MET
Q1 26
Q4 25
$3.3B
$7.1B
Q3 25
$2.8B
$3.6B
Q2 25
$2.0B
$2.2B
Q1 25
$1.4B
$4.3B
Q4 24
$2.9B
$4.6B
Q3 24
$2.7B
$4.2B
Q2 24
$2.0B
$3.5B
Free Cash Flow
ABT
ABT
MET
MET
Q1 26
Q4 25
$2.6B
Q3 25
$2.3B
Q2 25
$1.5B
Q1 25
$933.0M
Q4 24
$2.1B
Q3 24
$2.1B
Q2 24
$1.4B
FCF Margin
ABT
ABT
MET
MET
Q1 26
Q4 25
22.9%
Q3 25
20.2%
Q2 25
13.9%
Q1 25
9.0%
Q4 24
19.6%
Q3 24
20.2%
Q2 24
13.8%
Capex Intensity
ABT
ABT
MET
MET
Q1 26
Q4 25
6.0%
Q3 25
4.4%
Q2 25
4.5%
Q1 25
4.7%
Q4 24
6.6%
Q3 24
5.2%
Q2 24
5.1%
Cash Conversion
ABT
ABT
MET
MET
Q1 26
Q4 25
1.87×
8.75×
Q3 25
1.70×
3.98×
Q2 25
1.15×
3.00×
Q1 25
1.07×
4.51×
Q4 24
0.31×
3.63×
Q3 24
1.64×
3.11×
Q2 24
1.51×
3.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABT
ABT

Segment breakdown not available.

MET
MET

Premiums, fees and other revenues$14.3B75%
Other$4.8B25%

Related Comparisons